Oragenics revenue OGEN

Sales by quarter and over the last twelve months, from 2010.

Oragenics' revenue was $37.7K over the twelve months to Dec 31, 2023, down 71% on a year earlier.

In its latest quarter, Q4 FY23, it was $0.

Over the five fiscal years to FY2023 it shrank 47% a year on average.

Revenue over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Revenue	On a year earlier	Last 12 months
Q4 FY23	Dec 31, 2023	$0	n/a	$37.7K
Q3 FY23	Sep 30, 2023	$7.5K	−91%	$37.7K
Q2 FY23	Jun 30, 2023	$13.2K	−57%	$116.2K
Q1 FY23	Mar 31, 2023	$17K	+13%	$133.5K
Q4 FY22	Dec 31, 2022	$0	n/a	$131.5K
Q3 FY22	Sep 30, 2022	$86K	n/a	n/a
Q2 FY22	Jun 30, 2022	$30.4K	n/a	n/a
Q1 FY22	Mar 31, 2022	$15.1K	n/a	n/a
Q4 FY17	Dec 31, 2017	$0	n/a	$0
Q3 FY17	Sep 30, 2017	$0	n/a	$0
Q2 FY17	Jun 30, 2017	$0	n/a	$0
Q1 FY17	Mar 31, 2017	$0	n/a	$0

Companies in Healthcare nearest Oragenics' size, closest first, today.

Company	Revenue, 12 months	Growth
OGENOragenics	n/m
OXBROXBRIDGE RE HOLDINGS	$2.8M	+40% a year
EDUCEducational Development	$20M	−32% a year
GTIMGood Times Restaurants	$135.1M	−6% a year
MDRRMedalist Diversified	$9.6M	−1% a year
BCGBinah Capital	$191.9M	+8% a year
Peer median	$20M

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.